Researchers have shown that medicine designed at nanoscale offers unprecedented opportunities for targeted treatment of serious diseases such as cancer. However, research also shows that the body's immune system plays a part in the drug delivery process.
Merck KGaA has received a complete response letter from the U.S. Food and Drug Administration on the new drug application for Cladribine Tablets, its investigational oral formulation of cladribine, a therapy for relapsing-remitting multiple sclerosis.
The U.S. Food and Drug Administration approved Edarbi tablets to treat high blood pressure in adults. Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs.
The drugmaker Bristol-Myers Squibb Co. said that Elliott Sigal he been elected to its board of directors. Sigal, 59, is the company's chief scientific officer and the president of its research and development unit.
More than 2,000 HIV-positive people from India and other Asian nations marched in New Delhi to demand the Indian government reject provisions on pharmaceuticals in the India-European Union free trade agreement.
GTx Inc. said it is ending a development deal with drug maker Ipsen Ltd. over the bone drug toremifene. The drug is designed to reduce bone fractures in men who have prostate cancer and are being treated with androgen deprivation therapy.
Mylan Inc. said that it asked the Food and Drug Administration to approve a generic version of Noven Pharmaceuticals Inc.'s Vivelle-Dot estrogen patch, prompting patent lawsuits.
Biotechnology company Nektar Therapeutics reported a larger fourth-quarter loss as it moved to a new research and development facility. The company said it lost $22.6 million, or 24 cents per share.
Rigel Pharmaceuticals Inc. said lower costs and a tax credit left it with a smaller loss for the fourth quarter. The development stage company reported a net loss of $17.2 million, or 33 cents per share.
Drugmaker Merck & Co. said its planned venture with French counterpart Sanofi-Aventis SA to unite their animal health businesses has been delayed as regulators continue anti-trust reviews.
Bioo Scientific announced the launch of the NEXTflex DNA Sequencing Kits and NEXTflex DNA Barcodes, designed to provide flexibility and high-throughput capabilities in sequencing applications at a cost savings.
VICI Valco’s Cheminert C72 Ultra-high Pressure UHPLC Injector features a proprietary stator coating that permits pressures up to 15,000 or 20,000 psi. Many of the latest analytical techniques require systems that are capable of this much pressure.
The University of Notre Dame has added Caretream’s Albira system to its In Vivo Imaging Core, part of the Notre Dame Integrated Imaging Facility.
Agilent Technologies Inc. has acquired BIOCIUS Life Sciences, Inc., developer of the RapidFire high-throughput mass spectrometry drug-screening platform, and Lab901, a leading electrophoresis equipment and consumables company.
Parkinson's disease sufferers lack a sufficient amount of a brain chemical called dopamine. Previous research has shown that a novel protein known as protein kinase-C kills essential dopamine-producing cells in the brain.